Holen Sie sich die Stockscreener-App
16.91
24.98%
3.38
Handel nachbörslich:
16.89
-0.02
-0.12%
Schlusskurs vom Vortag:
$13.53
Offen:
$14.89
24-Stunden-Volumen:
2.62M
Relative Volume:
3.97
Marktkapitalisierung:
$923.23M
Einnahmen:
$8.78M
Nettoeinkommen (Verlust:
$-104.70M
KGV:
-7.135
EPS:
-2.37
Netto-Cashflow:
$-82.68M
1W Leistung:
+28.40%
1M Leistung:
+42.58%
6M Leistung:
+59.08%
1J Leistung:
+19.34%
1-Tages-Spanne:
$13.17
$17.61
1-Wochen-Bereich:
$12.86
$17.61
52-Wochen-Spanne:
$5.35
$17.61
Stoke Therapeutics Inc Stock (STOK) Company Profile
Firmenname
Stoke Therapeutics Inc
Sektor
Branche
Telefon
781-430-8200
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Vergleichen Sie STOK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
16.91 | 718.50M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-18 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-03-26 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-07-25 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Fortgesetzt | Canaccord Genuity | Buy |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-24 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Eingeleitet | Jefferies | Buy |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-11-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Eingeleitet | UBS | Neutral |
| 2021-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-12-11 | Bestätigt | Needham | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-29 | Eingeleitet | Needham | Buy |
| 2019-12-18 | Eingeleitet | Wedbush | Outperform |
| 2019-11-12 | Eingeleitet | BTIG Research | Buy |
| 2019-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Credit Suisse | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Stoke Therapeutics Reports 'Impressive' Data for Severe Epilepsy Treatment, Wedbush Says - MarketScreener
Stoke Therapeutics 2025 Q2 Earnings Net Income Cuts Loss by 8.6% - AInvest
Stoke Therapeutics Q2 Loss Narrows, Revenue Rises - 富途牛牛
Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Call Highlights: Strong Growth and Strategic ... - Yahoo Finance
Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - BioSpace
Stoke Therapeutics Impresses With Strong Results For Dravet Syndrome Drug - Finimize
Earnings call transcript: Stoke Therapeutics beats Q2 2025 expectations - Investing.com
Stoke Therapeutics shares rise 2.73% after-hours following positive Q2 results and Phase 3 trial initiation. - AInvest
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Stoke Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Stoke Therapeutics earnings beat by $0.10, revenue topped estimates - Investing.com Canada
STOKE THERAPEUTICS Earnings Results: $STOK Reports Quarterly Earnings - Quiver Quantitative
Stoke Therapeutics Q2 2025 slides: Phase 3 Dravet trial underway, ADOA program advances - Investing.com Canada
Stoke's Dravet Syndrome Treatment Shows 3-Year Durability as Pivotal Trial Begins - Stock Titan
Can Stoke Therapeutics Inc. outperform under higher oil pricesStrong Support Zone Stocks - thegnnews.com
First patient dosed in Phase III trial of zorevunersen for Dravet syndrome - Clinical Trials Arena
Stoke Therapeutics shares fall 2.74% premarket after dosing first patient in Phase 3 EMPEROR study of zorevunersen. - AInvest
Stoke Therapeutics Earnings Preview: Analyst Expectations and Market Sentiments - AInvest
A Look Ahead: Stoke Therapeutics's Earnings Forecast - 富途牛牛
Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome - Ariva
First Dravet syndrome patient dosed in Phase 3 trial of zorevunersen - Investing.com Canada
Biogen, Stoke dose first patient in phase 3 Dravet syndrome trial - Investing.com
Biogen and Stoke Therapeutics Announce First Patient Dosed - GlobeNewswire
Institutional scanner results for Stoke Therapeutics Inc.Asset Growth Pattern and Return Summary - Newser
Building trade automation scripts for Stoke Therapeutics Inc.Free Fundamental Growth Stock Analysis - Newser
Multi asset correlation models including Stoke Therapeutics Inc.Free Trend Following Strategy With Stop Loss - Newser
Can momentum traders help lift Stoke Therapeutics Inc.Free Wealth Building Stock Market Ideas - Newser
Will Stoke Therapeutics Inc. bounce back from current supportLow Drawdown Stock Screener with Analysis - Newser
Stoke Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayEquity Forecast with Predictive AI Screener - Newser
Stoke Therapeutics Inc. Outperforms Peers on Volume MetricsAccurate Buy Point for Momentum Stocks Detected - beatles.ru
Stoke Therapeutics STOK 2025Q2 Earnings Preview Upside Potential on Innovative Fluorescence Applications - AInvest
Stoke Therapeutics Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Stoke Therapeutics to Host Q2 2025 Business and Financial Update Webcast and Conference Call. - AInvest
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates - The Globe and Mail
Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference - BioSpace
Stoke Therapeutics to Showcase Dravet Syndrome RNA Treatment at Major Growth Conference - Stock Titan
Published on: 2025-08-05 00:18:53 - beatles.ru
Combining machine learning predictions for Stoke Therapeutics Inc.Predictive Short-Term Market Reversal Alerts - Newser
Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Trendline Breach Raises Concern for Stoke Therapeutics Inc. InvestorsVerified Signal From Chart Patterns Detected - metal.it
Should I hold or sell Stoke Therapeutics Inc. stock in 2025Maximize returns with strategic portfolio planning - Jammu Links News
Is Stoke Therapeutics Inc. a growth stock or a value stockRemarkable growth - Jammu Links News
Is it the right time to buy Stoke Therapeutics Inc. stockMaximize returns with expert trading insights - Jammu Links News
How many analysts rate Stoke Therapeutics Inc. as a “Buy”Invest confidently with data-driven strategies - Jammu Links News
What analysts say about Stoke Therapeutics Inc. stockRapid return acceleration - Jammu Links News
Does Stoke Therapeutics Inc. stock perform well during market downturnsAchieve breakthrough results with expert guidance - Jammu Links News
How strong is Stoke Therapeutics Inc. company’s balance sheetMaximize your portfolio’s growth potential - Jammu Links News
How volatile is Stoke Therapeutics Inc. stock compared to the marketUnlock expert insights for smarter investing - Jammu Links News
How does Stoke Therapeutics Inc. compare to its industry peersRapid wealth accumulation - Jammu Links News
What catalysts could drive Stoke Therapeutics Inc. stock higher in 2025Double or triple returns - Jammu Links News
Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):